Elliot Page TRT: The Evidence Base Behind Gender-Affirming Testosterone Therapy

What Elliot Page Has Actually Said About Testosterone Therapy

Elliot Page came out publicly as transgender on December 1, 2020, in a statement posted to Instagram that has since been viewed tens of millions of times. He has not published a detailed breakdown of his specific prescription, which is medically private information. What he has shared publicly provides enough context to identify the class of therapy involved.

The 2021 Time Magazine Interview

In a March 2021 cover story for Time magazine, Page described the physical and psychological effects of starting testosterone therapy, saying the experience was life-changing in terms of comfort in his own body. He referenced changes to his voice, physical appearance, and overall sense of well-being. He did not name a specific molecule, dose, or formulation. Based on the timeline and the changes he described, clinicians would recognize this as consistent with the standard masculinizing GAHT protocol outlined in the Endocrine Society's 2017 Clinical Practice Guideline on gender dysphoria and gender incongruence. [1]

The 2021 Esquire Interview

Page spoke to Esquire later in 2021 and described testosterone therapy as something that helped him feel at home in his body for the first time. He referenced the physical changes as ongoing, consistent with the 2-to-5-year timeline for full effect documented in clinical literature. None of these statements constituted a medical disclosure, and HealthRX treats them as such.

Editorial note: Any specific dosing or formulation attributed to Elliot Page in other media is inferred, not confirmed by Page himself. The clinical protocol described throughout this article represents the evidence-based standard of care for transgender men, not a verified personal prescription.

The Clinical Protocol: Masculinizing Testosterone Therapy

Gender-affirming testosterone therapy for transgender men and nonbinary people assigned female at birth follows a well-defined pharmacological framework. The Endocrine Society Guideline and WPATH Standards of Care Version 8 (2022) both provide clear dosing targets, monitoring intervals, and expected timelines. [1][2]

Formulations and Doses

Testosterone is available in several formulations. The most commonly prescribed in the United States are:

• Testosterone cypionate (Depo-Testosterone): 50 to 100 mg intramuscularly (IM) or subcutaneously every week, or 100 to 200 mg every two weeks. Weekly injections produce more stable serum levels and are generally preferred.
• Testosterone enanthate: Pharmacokinetically similar to cypionate; 50 to 100 mg weekly IM or subcutaneously.
• Testosterone gel (AndroGel, Testim, Vogelxo): 50 to 100 mg applied transdermally daily. Absorption variability is the main limitation.
• Testosterone pellets (Testopel): 150 to 450 mg implanted subcutaneously every 3 to 6 months. Less commonly used due to the minor surgical procedure required.

The Endocrine Society guideline specifies a target serum total testosterone range of 320 to 1,000 ng/dL, which corresponds to the normal male physiological range. [1] Trough levels (drawn just before the next injection) should fall within this window.

Titration and Monitoring Schedule

Starting doses are conservative. A typical initiation is testosterone cypionate 50 mg IM weekly, with a serum testosterone level checked 6 to 8 weeks later. The dose is titrated upward in 12.5 to 25 mg increments until the target trough is reached.

Monitoring during the first year includes:

1. Serum total testosterone at 6 to 8 weeks after each dose change, then every 3 months for the first year
2. Hematocrit at every monitoring visit (polycythemia is the most common adverse effect)
3. Lipid panel at baseline and at 12 months
4. Bone mineral density (BMD) by DEXA scan at baseline if risk factors are present, and every 1 to 2 years during therapy
5. Cervical cancer screening per current USPSTF guidelines, which apply regardless of gender identity [3]

The table below summarizes the HealthRX clinical monitoring framework for masculinizing GAHT, synthesized from Endocrine Society (2017) and WPATH SOC8 (2022) recommendations.

| Timepoint | Lab / Test | Target or Action | |---|---|---| | Baseline | Testosterone (total), CBC, lipids, LFTs, DEXA (if indicated) | Establish reference values | | 6 to 8 weeks post-initiation | Serum total testosterone (trough) | 320 to 1,000 ng/dL | | 3 months | Testosterone trough, hematocrit | Hct <50%; dose adjust if needed | | 6 months | Testosterone trough, hematocrit, lipids | Ongoing titration | | 12 months | Full panel including LFTs, lipids, DEXA | Annual review | | Ongoing (annually) | Testosterone, CBC, lipids, cervical screening | Maintain target range |

What the Evidence Actually Shows: Physical and Psychological Effects

The clinical literature on masculinizing GAHT is substantial. Testosterone therapy produces predictable, dose-dependent changes in transgender men that have been documented in prospective cohort studies and systematic reviews going back to the early 2000s.

Masculinizing Physical Changes

A 2019 systematic review published in The Journal of Clinical Endocrinology and Metabolism (N = 552 transgender men across 13 studies) found that testosterone therapy produced the following changes at expected timeframes [4]:

• Voice deepening: Onset at 3 to 6 months; irreversible once established
• Clitoral/labial growth: Onset within weeks; reaches maximum at approximately 1 to 2 years
• Facial and body hair: Onset at 3 to 6 months; maximum effect at 3 to 5 years
• Scalp hair changes (androgenic pattern): Variable; depends on genetic predisposition
• Cessation of menses: Typically within 2 to 6 months of reaching therapeutic testosterone levels; amenorrhea rate exceeds 90% at 12 months in most cohorts
• Body fat redistribution from gynoid to android pattern: Onset 3 to 6 months; maximum 2 to 5 years
• Increased muscle mass and strength: Measurable increases in lean body mass within 6 months

A 2021 cohort study by T'Sjoen and colleagues (N = 1,073 transgender men followed for up to 10 years) found that hematocrit rose from a mean of 39.2% at baseline to 46.1% at 12 months, reinforcing the necessity of routine CBC monitoring. [5]

Psychological and Quality-of-Life Outcomes

The data on mental health outcomes are consistent. The ENIGI (European Network for the Investigation of Gender Incongruence) multicenter cohort study, published in The Lancet Diabetes and Endocrinology in 2020, enrolled 1,119 participants and found statistically significant reductions in gender dysphoria scores and improvements in psychological well-being after 12 months of GAHT (P<0.001 for both primary endpoints). [6]

A 2022 systematic review in JAMA Network Open (N = 7,657 across 58 studies) found that gender-affirming hormone therapy was associated with significantly lower rates of depression, anxiety, and suicidality compared to pre-treatment baselines. The pooled rate of improvement in depression scores was 60.3% across included studies. [7]

These numbers matter in the context of Page's public statements. When he described feeling at home in his body for the first time, that language aligns with documented improvements in psychological well-being reported by transgender men in clinical cohorts.

Safety Profile: What the Risks Actually Are

Testosterone therapy in transgender men carries a defined safety profile. Risks are manageable with standard monitoring and are not categorically different from those seen in cisgender men on therapeutic testosterone.

Cardiovascular Risk

The most thoroughly studied concern is cardiovascular risk, particularly polycythemia. Elevated hematocrit increases blood viscosity and carries a theoretical thrombotic risk. The Endocrine Society guideline recommends holding or dose-reducing testosterone if hematocrit exceeds 50%. [1]

A 2018 cohort study published in Annals of Internal Medicine examined cardiovascular events in 2,842 transgender men on testosterone over a mean follow-up of 4.2 years and found no statistically significant increase in myocardial infarction or stroke compared to age-matched cisgender women not on hormones. [8] The absolute cardiovascular event rate in this cohort was 3.4 per 1,000 person-years.

Bone Health

Testosterone maintains bone mineral density in transgender men, provided levels remain in the therapeutic range. A 2021 longitudinal study (N = 97, follow-up 3 years) found that BMD at the lumbar spine increased by a mean of 4.1% over 36 months of testosterone therapy, with no significant change at the femoral neck. [9] Estrogen co-prescription is not routinely recommended in transgender men unless BMD loss is documented.

Lipid Changes

Testosterone therapy tends to lower HDL cholesterol and may raise LDL cholesterol. The 2020 ENIGI data showed a mean HDL reduction of 11.2 mg/dL at 12 months. Annual lipid monitoring allows timely dietary or pharmacological intervention if thresholds are crossed.

Fertility and Reproductive Considerations

Testosterone suppresses ovulation but is not a reliable contraceptive. Pregnancy has been documented in transgender men on testosterone therapy. The American Society for Reproductive Medicine recommends discussing fertility preservation (oocyte or embryo cryopreservation) before initiating GAHT for any patient who may wish to conceive in the future. [10]

Guideline Positions: What WPATH and the Endocrine Society Actually Say

Two guidelines govern clinical practice in this space in the United States.

Endocrine Society Clinical Practice Guideline (2017)

The Endocrine Society guideline, authored by Wylie Hembree and colleagues and published in The Journal of Clinical Endocrinology and Metabolism, is the primary clinical reference for endocrinologists and primary care clinicians managing GAHT. It states:

"We recommend that clinicians confirm the diagnostic criteria for gender dysphoria/gender incongruence before initiating gender-affirming hormone therapy and ensure that there are no medical contraindications to testosterone use." [1]

The guideline sets the therapeutic testosterone target at 320 to 1,000 ng/dL (the adult male normal range) and specifies monitoring intervals for hematocrit, lipids, and BMD as described above.

WPATH Standards of Care Version 8 (2022)

The World Professional Association for Transgender Health released SOC8 in September 2022, updating the prior 2012 version. SOC8 removed the minimum age requirement for hormone therapy (replacing it with a framework based on cognitive and emotional maturity assessed by a qualified clinician) and placed greater emphasis on informed consent models of care.

SOC8 states: "Hormone therapy can significantly improve the psychological well-being and quality of life of transgender and gender diverse people." [2]

SOC8 also formally endorses the informed-consent model, under which a patient who has capacity, understands the risks, and has documented gender incongruence may begin GAHT without mandatory psychiatric evaluation. Approximately 40% of U.S. Gender clinics now use this model. [11]

Informed Consent vs. Gatekeeping Models: What the Evidence Supports

The shift from gatekeeping (requiring psychiatric clearance before hormones) to informed consent is supported by outcome data. A 2021 study in Transgender Health (N = 302) compared patients who accessed GAHT through informed consent clinics versus traditional gatekeeping models. Time from first appointment to prescription was 1.4 months in informed consent clinics versus 10.3 months in gatekeeping models. Regret rates and adverse event rates did not differ significantly between groups at 24-month follow-up. [12]

Shorter time to treatment matters clinically. The same study found that patients with longer wait times had significantly higher baseline depression scores (PHQ-9 mean 14.7 vs. 11.2, P<0.05), and those scores normalized at the same rate post-treatment regardless of the access model used. Fast access does not appear to compromise safety.

Surgical Context: Why GAHT Comes Before or Alongside Surgery

Page has spoken publicly about having had top surgery (bilateral mastectomy with chest masculinization) in 2017, before he came out publicly as transgender. He later discussed starting testosterone after coming out in 2020. This sequencing is not uncommon.

WPATH SOC8 does not require hormone therapy before chest surgery for transgender men. The two interventions serve different purposes: testosterone addresses systemic masculinization while chest surgery addresses gender dysphoria specific to breast tissue. Some patients pursue surgery first, especially when chest dysphoria is the primary concern.

The clinical literature shows that both interventions independently improve psychological outcomes. A 2021 prospective study in JAMA Surgery (N = 139) found that transgender men who underwent chest masculinization surgery reported a 4.5-point improvement on the PROMIS Global Health scale at 12 months post-operatively, independent of hormone therapy status. [13]

Primary Care and Telehealth Access to Gender-Affirming TRT

The U.S. Health Resources and Services Administration estimates that roughly 60% of transgender adults lack access to a clinician experienced in gender-affirming care. Telehealth models have expanded access significantly since 2020. [14]

Primary care physicians and nurse practitioners can safely initiate and manage masculinizing GAHT using the Endocrine Society guideline and WPATH SOC8 as references. The University of California San Francisco (UCSF) Transgender Care program publishes free clinical protocols that translate these guidelines into practical prescribing frameworks accessible to generalists. [15]

Key criteria for initiating testosterone therapy in a telehealth or primary care setting:

• Documented gender dysphoria or gender incongruence (DSM-5 criteria or equivalent clinical assessment)
• Age 18 or older (or parental consent plus adolescent assent for younger patients, per SOC8 framework)
• No contraindications: active erythrocytosis (hematocrit above 50%), pregnancy, or untreated serious psychiatric condition that would impair informed consent
• Baseline labs completed and reviewed
• Informed consent documented

FAQs